Showing results (771-780 of 2,357) with videos related to
Sort By:
Pageof 236
Clinical Neuropharmacology|January 1, 1983
Is baclofen an analgesic?C F Terrence, D M Potter, G H FrommClinical Neuropharmacology|January 1, 1983
Effect of decortication on striatal dopamine turnoverM Globus, E Melamed, N ConfortiClinical Neuropharmacology|October 19, 2016
Hemifacial Spasm From Lyme Disease: Antibiotic Treatment Points to the CauseTessa M LeWittClinical Neuropharmacology|December 13, 2016
Efficacy of the Treatments Used in Multiple Sclerosis: From Meta-analysis to Number Needed to TreatAntonio J García-Ruiz, Guillermo Izquierdo-Ayuso, Guillermo Navarro-Mascarell, et al.Clinical Neuropharmacology|November 24, 2016
Switching L-dopa Therapy from Pulsatile to Pulse Administration Reduces Motor Complications in Parkinson's DiseaseGiovanni Mostile, Alessandra Nicoletti, Valeria Dibilio, et al.Clinical Neuropharmacology|November 24, 2016
Fingolimod Use for the Treatment of Multiple Sclerosis in a Clinical Practice Setting in MadridVictoria Galán Sánchez-Seco, Ignacio Casanova-Peño, Roberto Álvarez-Lafuente, et al.Clinical Neuropharmacology|November 24, 2016
No Superiority of Treatment With Osmotic Controlled-Release Oral Delivery System-Methylphenidate Over Short/Medium-Acting Methylphenidate Preparations in the Rate and Timing of Injuries in Children With Attention-Deficit/Hyperactivity DisorderPavel Golubchik, Arad Kodesh, Abraham WeizmanClinical Neuropharmacology|March 12, 2014
Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson disease: an open-label observational studyItay Lotan, Therese A Treves, Yaniv Roditi, et al.Clinical Neuropharmacology|March 12, 2014
Ropinirole-induced Pisa syndrome in Parkinson diseaseSalvatore Galati, Jens Carsten Möller, Claudio StädlerClinical Neuropharmacology|March 12, 2014
Focal myositis of lower extremity responsive to botulinum A toxinJosko Mitrovic, Zeljko Prka, Rado Zic, et al.Pageof 236